INFECTIONS AND OTHER LUNG DISEASES USING MODELS OF HUMAN LUNG TISSUE GROWN FROM STEM CELLS
Dr Rhiannon Werder,
Team Leader
Murdoch Children’s Research Institute
Melbourne, Victoria, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | February 2025
Released on the United Nations International Day of Women and Girls in Science, 11th February 2025 @WomenScienceDay
Dr Rhiannon Werder is a Team Leader at Murdoch Children’s Research Institute leading a multidisciplinary team, combining expertise in stem cell biology and immunology, to develop new therapies for lung diseases. Her research centres around induced pluripotent stem cells to investigate respiratory diseases, spanning acute respiratory infections to chronic lung diseases. Using stem cells, Dr Werder’s team creates models of human lung tissue. With these models, Dr Werder is investigating how human-specific pathogens infect different regions of the lung, the ensuing immune responses, and how the lung repairs itself after infections, especially in people with preexisting lung diseases.
After completing her PhD in Mucosal Immunology at the University of Queensland, Dr Werder was awarded a NHMRC CJ Martin Fellowship to undertake postdoctoral training at the Center for Regenerative Medicine at Boston University. At the height of the COVID-19 pandemic, Dr Werder’s research led to significant findings, including the first discovery of how the lung epithelium responds to the SARS-CoV-2 virus. She has also pioneered new gene-editing techniques in iPSC-derived epithelial cells to understand chronic lung disease inception. The impact of her research has been recognised by prestigious awards including the Metcalf Prize for Stem Cell Research by National Stem Cell Foundation of Australia.
https://orcid.org/0000-0002-6432-4587
-
Applying nanotechnology to chronic pain management
Dr Felicity Han is a Research Fellow and Leader in Pain Relief Innovation, at the Australian Institute for Bioengineering and Nanotechnology in the University of Queensland. Dr Han’s research interests sit at the interface of drug delivery and the pain field. Her overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management.
-
Superslayer taking on antibiotic-resistant bacteria
Dr Katharina Richter is a visionary leader in MedTech, acclaimed for innovation and gender diversity. With over 40 awards to her name, including MIT Innovator Under 35 Asia-Pacific, and Prime Minister’s Prize for New Innovator finalist, she has shattered barriers as an entrepreneur, scientist, and ‘superbug slayer.’ Katharina’s groundbreaking work in combating antibiotic-resistant bacteria has resulted in 6 innovative treatments, 3 of which are patented, offering hope against deadly infections.
-
CASE STUDY: Transforming surgical waitlist into a ‘preparation list’
The DIAMONDS initiative aims to transform the surgical waitlist into a “preparation list,” enabling healthcare professionals to optimise patient care in the months leading up to elective surgery starting at pre-admission phase.
Patients are will be able to complete pre-admission forms online, receive timely updates, and access educational resources to ensure thorough preparation. This will allow staff to spend more time with patients.
